A 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting

Table 3 Adverse events occurring at an incidence ≥5%

Adverse event	n (%)
Headache	28 (11.4)
Hallucination, auditory	26 (10.6)
Insomnia	26 (10.6)
Constipation	23 (9.4)
Akathisia	14 (5.7)
Extrapyramidal disorder	13 (5.3)
Upper respiratory tract infection	13 (5.3)
Tremor	13 (5.3)

ISSN: 1744-859X